New drug siplizumab tested in ALS patients – early trial begins

NCT ID NCT06453668

Terminated Disease control Sponsor: ITB-Med LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-stage trial tests the safety of siplizumab, a drug that may calm the immune system, in 48 adults newly diagnosed with ALS. Researchers will monitor side effects and how the drug moves through the body. The goal is to see if it is safe enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: siplizumab (TCD601)
What this could lead to: If safe and effective, siplizumab could slow ALS progression by targeting the immune system, offering a new treatment option.
What could go wrong: This is an early Phase 1 trial with only 48 people, focused on safety. It may not show benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS

Contacts and locations

Locations

Skåne University Hospital Malmö

Malmö, 205 02, Sweden
Studieenheten Akademiskt Specialistcentrum

Stockholm, 171 77, Sweden
Umeå University Hospital

Umeå, 901 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.